SUN S KIM, RN PC
Physician Assistant at Shrewsbury St, Worcester, MA

4767858, Aug 30, 1988

May 14, 1987

7/050195

Sun H. Kim - Chestnut Hill MA

Biomeasure, Incorporated - Hopkinton MA

C07D41714, C07D51314, C07D48704

544 34

The invention features compounds having anti-arthritic activity and having the formula ##STR1## wherein X is an alkyl group having between 1 and 8, inclusive, carbon atoms and Y is a hydroxyalkylamino group having between 2 and 8, inclusive, carbon atoms; a dialkylamino group having between 2 and 12, inclusive, carbon atoms; a carboxyalkylamino group having between 2 and 9, inclusive, carbon atoms; a heterocycloalkyl group having between 2 and 5, inclusive, carbon atoms and having nitrogen as a hetero atom; an alkylthioalkylamino group having between 3 and 10, inclusive, carbon atoms; or a heteroarylalkylthioalkylamino group having between 5 and 14, inclusive, carbon atoms and having nitrogen as a hetero atom. The invention further features compounds having similar activity and having the formula ##STR2## wherein A is H, an alkyl group having between 1 and 8, inclusive, carbon atoms, an aralkyl group having between 6 and 14, inclusive, carbon atoms, an aryl group having between 5 and 14, inclusive, carbon atoms, or a heteroaryl group having between 3 and 12, inclusive, carbon atoms and having nitrogen as a hetero atom; and B is H, benzyl, a carboalkoxy group having between 2 and 8, inclusive, carbon atoms, an alkyl group having between 1 and 8, inclusive, carbon atoms, or an alkyl group having between 3 and 8, inclusive, carbon atoms. The invention additionally features compounds having similar activity and having the formula ##STR3## wherein r is an integer between 2 and 4, inclusive.

6307017, Oct 23, 2001

Mar 2, 1999

9/260846

David H. Coy - New Orleans LA
Jacques-Pierre Moreau - Upton MA
Sun Hyuk Kim - Chestnut Hill MA

Biomeasure, Incorporated - Milford MA
The Administrators of the Tulane Educational Fund - New Orleans LA

A61K 3800, A61K 3804, C07K 500, C07K 700

530328

A linear (i. e. , non-cyclic) analog of biologically active amphibian bombesin, mammalian gastrin-releasing peptide (GRP), or mammalian growth hormone releasing factor (GRF), having an active site and a binding site responsible for the binding of the peptide to a receptor on a target cell. Cleavage of a peptide bond in the active site of naturally occurring bombesin, GRP, or GRF is unnecessary for in vivo biological activity. The analog has one of the following modifications: (a) a deletion of an amino acid residue within the active site and a modification of an amino acid residue outside of the active site, (b) a replacement of two amino acid residues within the active site with a synthetic amino acid, a. beta. -amino acid, or a. gamma. -amino acid residue, or (c) a non-peptide bond instead of a peptide bond between an amino acid residue of the active site and an adjacent amino acid residue.

4957915, Sep 18, 1990

Feb 27, 1989

7/316463

Sun H. Kim - Chestnut Hill MA
John E. Taylor - Upton MA

Biomeasure, Inc. - Hopkinton MA

C07D24314, A61K 3155

514221

BZDs of the general formula 1: ##STR1## where: R represents H, alkyl, alkenyl, cycloalkyl or cycloalkenyl each with up to 8 carbon atoms, phenylalkyl with an alkylene chain of 1 to 3 carbon atoms and optionally substituted on the phenyl radical with one or two substituents selected from the group consisting of Cl, Br, F, CN, CF. sub. 3, NO. sub. 2, lower alkyl, and OCH. sub. 3, or represents a phenyl radical which is optionally substituted with one or two substituents selected from the group consisting of Cl, F, Br, CN, I, CF. sub. 3 NO. sub. 2, lower alkyl and OCH. sub. 3, or represents a 5-membered or 6-membered heterocyclic radical with 1 or 2 heteroatoms from the group consisting of O, N and S; R. sub. 1 represents H or, together with R. sub. 2, forms a bond; R. sub. 2 and R. sub.

4496540, Jan 29, 1985

Dec 30, 1982

6/454731

Sun K. Kim - Chestnut Hill MA

Biomeasure, Inc. - Hopkinton MA

C07C10352, A61K 3702

514 19

In one aspect, compounds capable of inhibiting an endopeptidase responsible for a degradation pathway of enkephalin and having the general formula A--B--NHOH wherein A is one of the aromatic group-containing amino acid residues L-tryptophyl, D-tryptophyl, L-tyrosyl, D-tyrosyl, L-phenylalanyl, or D-phenylalanyl, and B is one of the amino acids glycine, L-alanine, D-alanine, L-leucine, D-leucine, L-isoleucine, or D-isoleucine; or a pharmaceutically acceptable salt thereof.

4983567, Jan 8, 1991

May 25, 1989

7/357179

Sun H. Kim - Chestnut Hill MA

Biomeasure, Inc. - Hopkinton MA

C07C 8310

562623

A compound having the formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein A is an amino acid identifying group; B is a hydrogen atom, an alkyl group having 1-5, inclusive, carbon atoms, or an aralkyl group having 6-12, inclusive, carbon atoms; carbon atom 2 is of the R configuration; and carbon atom 3 is of the R configuration.

5750646, May 12, 1998

Mar 22, 1995

8/408197

David H. Coy - New Orleans LA
Jacques-Pierre Moreau - Upton MA
John E. Taylor - Upton MA
Sun Hyuk Kim - Chestnut Hill MA

The Administrators of the Tulane Educational Fund - New Orleans LA
Biomeasure, Inc. - Hopkinton MA

A61K 3800, C07K 500, C07K 700, C07K 1700

530314

A linear peptide which is an analog of a naturally occurring, biologically active peptide having an active site and a binding site responsible for the binding of the peptide to a receptor on a target cell, cleavage of a peptide bond in the active site to the naturally occurring peptide being unnecessary for in vivo biological activity, the analog having a non-peptide bond instead of a peptide bond between an amino acid of the active site and an adjacent amino acid, and having the same binding site as the naturally occurring peptide, so that the analog is capable of acting as a competitive inhibitor of the naturally occurring peptide by binding to the receptor and, by virtue of the non-peptide bond, failing to exhibit the in vivo activity of the naturally occurring peptide.

5877277, Mar 2, 1999

Nov 10, 1994

8/337127

David H. Coy - New Orleans LA
Jacques-Pierre Moreau - Upton MA
Sun Hyuk Kim - Chestnut Hill MA

Biomeasure, Inc. - Hopkington MA
Administrators of the Tulane Educational Fund - New Orleans LA

C07K 500, C07K 700, C07K 706, A61K 3800

530328

A linear (i. e. , non-cyclic) analog of biologically active amphibian bombesin, mammalian gastrin-releasing peptide (GRP), or mammalian growth hormone releasing factor (GRF), having an active site and a binding site responsible for the binding of the peptide to a receptor on a target cell. Cleavage of a peptide bond in the active site of naturally occurring bombesin, GRP, or GRF is unnecessary for in vivo biological activity. The analog has one of the following modifications: (a) a deletion of an amino acid residue within the active site and a modification of an amino acid residue outside of the active site, (b) a replacement of two amino acid residues within the active site with a synthetic amino acid, a. beta. -amino acid, or a. gamma. -amino acid residue, or (c) a non-peptide bond instead of a peptide bond between an amino acid residue of the active site and an adjacent amino acid residue.

4814463, Mar 21, 1989

Dec 31, 1985

6/815217

Sun H. Kim - Chestnut Hill MA

Biomeasure, Inc. - Hopkinton MA

C07K 506

548495

In general, the invention features CCK antagonist compounds having the formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein each R. sup. 1 is, independently, an alkyl group having 1 to 5, inclusive, carbon atoms, an alkoxy group having 1 to 5, inclusive, carbon atoms, a halogen, amino, hydroxy, nitro, cyano, carboxyl, trifluoromethyl, ethyl carboxylate, or a hydrogen; m is an integer between 0 and 2, inclusive; and A is either ##STR2## where n is an integer between 1 and 5, inclusive, and R. sup. 2 is hydroxy, an alkoxy group having 1 to 5, inclusive, carbon atoms, aralkoxy (e. g. , benzyloxy), aralkyl (e. g. , benzyl), amino, an alkyl group having 1 to 5, inclusive, carbon atoms, an alkylamino group having 1 to 5, inclusive, carbon atoms, a dialkylamino group with each alkyl group, independently having 1 to 5, inclusive, carbon atoms, a cycloalkylamino group wherein the ring has 4 to 6, inclusive, carbon atoms (e. g. , pyrrolidino, piperidino, N-methylpiperazino), or morpholino; or A is an alkyl group having 1 to 5, inclusive, carbon atoms, a hydroxyalkyl group having 1 to 5, inclusive, carbon atoms, an alkoxyalkyl group having 2 to 8, inclusive, carbon atoms, an aralkoxyalkyl having 8 to 14, inclusive, carbon atoms, in aryl group (e. g. , phenyl, toluyl) having 6 to 14, inclusive, carbon atoms, an aralkyl group (e. g.

4814335, Mar 21, 1989

Jun 23, 1987

7/066262

Sun H. Kim - Chestnut Hill MA

Biomeasure, Incorporated - Hopkinton MA

A61K 31505, C07D48700

514257

In one aspect, compounds having antiviral activity and having the general formula: ##STR1## wherein each R. sup. 2, independently, is H or lower (fewer than 6 carbon atoms) alkyl; each R. sup. 3, independently, is H or lower alkyl; R. sup. 0 is H or lower alkyl; R. sup. 1 is H or lower alkyl; 1. ltoreq. n. ltoreq. 11; n-2. ltoreq. m. ltoreq. 2n; 0. ltoreq. p. ltoreq. 3; z is 0 or 1; and p. ltoreq. 1. ltoreq. 2p; each n, m, p, and q being selected so that the sp. sup. 3 valence shell of each carbon atom in each ring is filled; or a pharmaceutically acceptable salt thereof.